A Phase 2 Study of Chronocort®, a Modified Release Formulation of Hydrocortisone, in the Treatment of Adults with Classic Congenital Adrenal Hyperplasia

被引：0
|
作者：
Mallappa, Ashwini [1 ]
Daley, Lori-Ann [1 ]
Sinaii, Ninet [1 ]
Van Ryzin, Carol [1 ]
Huatan, Hiep [2 ]
Digweed, Dena [2 ]
Eckland, David [2 ]
Whitaker, Martin [2 ]
Nieman, Lynnette K. [1 ]
Ross, Richard J. [3 ]
Merke, Deborah P. [1 ]
机构：
[1] NIH, Bethesda, MD 20892 USA
[2] Diurnal Ltd, Cardiff, S Glam, Wales
[3] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
ENDOCRINE REVIEWS | 2014年 / 35卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OR02-5
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia
    Dauber, Andrew
    Feldman, Henry A.
    Majzoub, Joseph A.
    INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY, 2010,
  • [22] A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (ChronocortTM) vs. conventional hydrocortisone (CortefTM) in the treatment of congenital adrenal hyperplasia
    Verma, Somya
    VanRyzin, Carol
    Sinaii, Ninet
    Kim, Mimi S.
    Nieman, Lynnette K.
    Ravindran, Shayna
    Calis, Karim A.
    Arlt, Wiebke
    Ross, Richard J.
    Merke, Deborah P.
    CLINICAL ENDOCRINOLOGY, 2010, 72 (04) : 441 - 447
  • [23] Iatrogenic Cushing syndrome in a girl with classic congenital adrenal hyperplasia treated with a homemade hydrocortisone solution
    Al-Rayess, Heba
    Fleissner, Kristin
    Brundage, Richard C.
    Sarafoglou, Kyriakie
    HORMONE RESEARCH IN PAEDIATRICS, 2020, 93 : 99 - 100
  • [24] Invited Commentary: A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia
    Speiser, Phyllis W.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (10):
  • [25] Treatment and health outcomes in adults with congenital adrenal hyperplasia
    Thang S. Han
    Brian R. Walker
    Wiebke Arlt
    Richard J. Ross
    Nature Reviews Endocrinology, 2014, 10 : 115 - 124
  • [26] Treatment and health outcomes in adults with congenital adrenal hyperplasia
    Han, Thang S.
    Walker, Brian R.
    Arlt, Wiebke
    Ross, Richard J.
    NATURE REVIEWS ENDOCRINOLOGY, 2014, 10 (02) : 115 - 124
  • [27] Challenges in treatment of patients with non-classic congenital adrenal hyperplasia
    Adriaansen, Bas P. H.
    Schroder, Mariska A. M.
    Span, Paul N.
    Sweep, Fred C. G. J.
    van Herwaarden, Antonius E.
    Claahsen-van der Grinten, Hedi L.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [28] Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia
    Sarafoglou, Kyriakie
    Jaber, Mutaz M.
    Al-Kofahi, Mahmoud
    Brundage, Richard C.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 183 (06) : L27 - L28
  • [29] Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia
    Tschaidse, Lea
    Reisch, Nicole
    Arlt, Wiebke
    de la Perriere, Aude Brac
    Hirschberg, Angelica Linden
    Juul, Anders
    Mallappa, Ashwini
    Merke, Deborah P.
    Newell-Price, John D. C.
    Perry, Colin G.
    Prete, Alessandro
    Rees, D. Aled
    Stikkelbroeck, Nike M. M. L.
    Touraine, Philippe A.
    Coope, Helen
    Porter, John
    Ross, Richard John M.
    Quinkler, Marcus
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2023, 188 (01)
  • [30] THE ADJUNCTIVE THERAPY PREFERENCES OF ADULTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA: A DISCRETE CHOICE EXPERIMENT
    Macey, J.
    Farrar, M.
    O'Donoghue, C.
    Knight, S.
    Carmichael, C.
    Marshall, C.
    Yonan, C.
    Imel, E.
    Salam, M.
    Mulhern, B.
    VALUE IN HEALTH, 2022, 25 (07) : S562 - S562
12345